BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-995@pharmaconomics
DTSTAMP:20260707T033829Z
DTSTART;VALUE=DATE:20260331
DTEND;VALUE=DATE:20260401
SUMMARY:BEAM Phase 2 — BEAM-302 (estimated date)
DESCRIPTION:Phase 2 trial results for BEAM-302 in alpha-1 antitrypsin deficiency are due ~ Mar 31\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1745999/000119312526065191/beam-ex99_1.htm\n\nTrack it: https://pharmaconomics.com/e/995
URL:https://pharmaconomics.com/e/995
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:BEAM catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR